Bilaketaren emaitzak - Daniel C Malone

Cost-Effectiveness Analysis of a Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder nork Fulton F. Velez, Daniel C. Malone

Connect to this object online.

Interpretable Machine Learning Prediction of Drug-Induced QT Prolongation: Electronic Health Record Analysis nork Steven T Simon, Katy E Trinkley, Daniel C Malone, Michael Aaron Rosenberg

Connect to this object online.

A systematic review of real-world healthcare resource use and costs of Clostridioides difficile infections nork Daniel C. Malone, Edward P. Armstrong, Dan Gratie, Sissi V. Pham, Alpesh Amin

Connect to this object online.

Societal perspectives on disease and treatment attributes characterizing rare diseases: a qualitative study from the United States nork Shelagh M. Szabo, Ivana F. Audhya, David Feeny, Peter Neumann, Daniel C. Malone, Katherine L. Gooch

Connect to this object online.

Short-term efficacy of non-pharmacological interventions for global population with elevated blood pressure: A network meta-analysis nork Taihang Shao, Leyi Liang, Chengchao Zhou, Yaqian Tang, Wenqing Gao, Yusi Tu, Yue Yin, Daniel C. Malone, Wenxi Tang, Wenxi Tang

Connect to this object online.

Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients nork Daniel C. Malone, Rebecca Dean, Ramesh Arjunji, Ivar Jensen, Phil Cyr, Beckley Miller, Benit Maru, Douglas M. Sproule, Douglas E. Feltner, Omar Dabbous

Connect to this object online.

Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States nork Alexa C. Klimchak, Lauren E. Sedita, Louise R. Rodino-Klapac, Jerry R. Mendell, Craig M. McDonald, Katherine L. Gooch, Daniel C. Malone

Connect to this object online.

Estimating health state utilities in Duchenne muscular dystrophy using the health utilities index and EQ-5D-5L nork Ivana F. Audhya, Shelagh M. Szabo, Andrea Bever, Fiona O'Sullivan, Daniel C. Malone, David Feeny, Peter Neumann, Susan T. Iannaccone, P. Jayasinghe, Katherine L. Gooch

Connect to this object online.

An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and... nork Rebecca Dean, Ivar Jensen, Phil Cyr, Beckley Miller, Benit Maru, Douglas M. Sproule, Douglas E. Feltner, Thomas Wiesner, Daniel C. Malone, Matthias Bischof, Walter Toro, Omar Dabbous

Connect to this object online.

A Minimal Information Model for Potential Drug-Drug Interactions nork Harry Hochheiser, Harry Hochheiser, Xia Jing, Elizabeth A. Garcia, Serkan Ayvaz, Ratnesh Sahay, Michel Dumontier, Juan M. Banda, Oya Beyan, Mathias Brochhausen, Evan Draper, Sam Habiel, Oktie Hassanzadeh, Maria Herrero-Zazo, Brian Hocum, John Horn, Brian LeBaron, Daniel C. Malone, Øystein Nytrø, Thomas Reese, Katrina Romagnoli, Jodi Schneider, Louisa (Yu), Richard D. Boyce, Richard D. Boyce

Connect to this object online.